Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

Simple item page
dc.contributor.authorTuboi, Suely H.
dc.contributor.authorSchechter, Mauro
dc.contributor.authorMcGowan, Catherine C.
dc.contributor.authorCesar, Carina
dc.contributor.authorKrolewiecki, Alejandro J.
dc.contributor.authorCahn, Pedro
dc.contributor.authorWolff, Marcelo
dc.contributor.authorPape, Jean W.
dc.contributor.authorPadgett, Denis
dc.contributor.authorSierra Madero, Juan
dc.contributor.authorGotuzzo, Eduardo
dc.contributor.authorMasys, Daniel R.
dc.contributor.authorShepherd, Bryan E.
dc.date.accessioned2024-05-23T18:53:34Z
dc.date.available2024-05-23T18:53:34Z
dc.date.issued2009
dc.description.abstractBackground: Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described. Methods: Five thousand one hundred fifty-two HIV-infected, antiretroviral-naive adults from clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru starting HAART during 1996-2007 were included. First-year mortality rates and their association with demographics, regimen, baseline CD4, and clinical stage were assessed. Results: Overall 1-year mortality rate was 8.3% [95% confidence interval (CI): 7.6% to 9.1%], although variable across sites: 2.6%, 3.7%, 6.0%, 13.0%, 10.8%, 3.5%, and 9.8% for clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru, respectively. Eighty percent of deaths occurred within the first 6 months. Median baseline CD4 was 107 cells per milliliter, ranging from 79 (Peru) to 163 (Argentina). Mortality estimates adjusting for CD4 were similar across sites (1.1%-2.8% for CD4 = 200), except for Haiti, 7.5%, and Honduras, 7.0%. Death was associated with lower CD4 [adjusted hazard ratio for CD4 = 200 vs. CD4 = 50 was 0.58; 95% CI: 0.40 to 0.85] and clinical AIDS (hazard ratio = 3.1; 95% CI: 2.1 to 4.5). Conclusions: Mortality rates were similar to those reported elsewhere for resource-limited settings. Disease stage at HAART initiation, treatment eligibility criteria, program age, and background mortality rates may explain some variability in prognosis between sites.
dc.identifier.citationTuboi, S. H., Schechter Mauro, McGowan Catherine C, Cesar Carina, Krolewiecki Alejandro J., Cahn, P., ... Masys, D. (2009). Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. JAIDS Journal of Acquired Immune Deficiency Syndromes.
dc.identifier.otherDOI: 10.1097/QAI.0b013e3181a44f0a
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1119
dc.relation.ispartofseriesJAIDS Journal of Acquired Immune Deficiency Syndromes
dc.subjectMortality
dc.subjectPotent Antiretroviral Therapy
dc.subjectLatin America
dc.subjectCaribbean
dc.subjectFirst Year
dc.titleMortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
167_2009_ Tuboi_Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean.pdf
Size:
875.77 KB
Format:
Adobe Portable Document Format
Download

Collections

Articulos científicos